In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, ProQR Therapeutics N.V (NASDAQ: PRQR) closed at $2.07 down -1.43% from its previous closing price of $2.1. In other words, the price has decreased by -$1.43 from its previous closing price. On the day, 0.81 million shares were traded. PRQR stock price reached its highest trading level at $2.12 during the session, while it also had its lowest trading level at $1.9.
Ratios:
For a deeper understanding of ProQR Therapeutics N.V’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.76 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.16.
On April 29, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $5.
Citigroup Upgraded its Neutral to Buy on March 10, 2025, while the target price for the stock was maintained at $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRQR now has a Market Capitalization of 218062176 and an Enterprise Value of 115159184. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.17 while its Price-to-Book (P/B) ratio in mrq is 2.77. Its current Enterprise Value per Revenue stands at 6.719 whereas that against EBITDA is -2.808.
Stock Price History:
The Beta on a monthly basis for PRQR is 0.23, which has changed by 0.1311475 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, PRQR has reached a high of $4.62, while it has fallen to a 52-week low of $1.07. The 50-Day Moving Average of the stock is -4.66%, while the 200-Day Moving Average is calculated to be 0.71%.
Shares Statistics:
For the past three months, PRQR has traded an average of 321.52K shares per day and 376410 over the past ten days. A total of 105.34M shares are outstanding, with a floating share count of 70.41M. Insiders hold about 33.08% of the company’s shares, while institutions hold 37.87% stake in the company. Shares short for PRQR as of 1756425600 were 549675 with a Short Ratio of 3.75, compared to 1753920000 on 375096. Therefore, it implies a Short% of Shares Outstanding of 549675 and a Short% of Float of 0.73.
Earnings Estimates
The firm’s stock currently is rated by 1.0 analysts. The consensus estimate for the next quarter is -$0.11, with high estimates of $0.04 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.31 and -$0.6 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.58, with 8.0 analysts recommending between -$0.38 and -$0.81.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $7.05M this quarter.It ranges from a high estimate of $12.06M to a low estimate of $5.1M. As of the current estimate, ProQR Therapeutics N.V’s year-ago sales were $4.15MFor the next quarter, 5 analysts are estimating revenue of $6.09M. There is a high estimate of $12.06M for the next quarter, whereas the lowest estimate is $2.8M.
A total of 5 analysts have provided revenue estimates for PRQR’s current fiscal year. The highest revenue estimate was $34.29M, while the lowest revenue estimate was $19.83M, resulting in an average revenue estimate of $23.34M. In the same quarter a year ago, actual revenue was $21.34MBased on 5 analysts’ estimates, the company’s revenue will be $20.4M in the next fiscal year. The high estimate is $24.72M and the low estimate is $11.08M.
